Shots:

• Biocon has received EMA’s certificate of GMP compliance from European inspection authority- Health Products Regulatory Authority (Ireland) and expand its capacities multi-fold with the new large-scale devices facility to meet the need of patients with diabetes in EU
• The manufacturing facility at Malaysia was inspected in May’2019 and is Asia's largest integrated insulins facility and manufactures Drug Substance and Drug Products in vials- cartridges and insulin delivery devices including recombinant human Insulin (rh-Insulin) and Insulin Glargine
• Biocon & Mylan’s Semglee- a biosimilar to Sanofi’s Lantus is an approved therapy in 60+ countries including its EMA’s approval in Mar’2018 and is available in key EU markets by Mylan since Nov’2018

Click here to­ read full press release/ article | Ref: Biocon | Image: Different Strokes